(FM) Inmunología
Departamento académico
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (10)
2024
2023
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
2021
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
2015
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine
2010
-
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009
Cancer Immunology, Immunotherapy
2006
-
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma
Cancer Research, Vol. 66, Núm. 4, pp. 2442-2450
2000
-
Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte?
Gene Therapy, Vol. 7, Núm. 14, pp. 1167-1170